arGentis™ Pharmaceuticals was established in 2007 to develop pharmaceuticals that address unmet medical needs. Our current treatments are based upon discoveries by researchers at the University of Tennessee College of Medicine in Memphis, TN, which is the medical college for West Tennessee and is both a teaching institution and a research institution. Most of the professors also actively practice medicine in the numerous hospitals in Memphis, TN.
Our mission is to develop and commercialize these treatments to improve the health and quality of life of the targeted patient groups and provide a fair return to our investors. The current focus is on autoimmune diseases treated primarily by Rheumatologists.
arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable the Company to obtain marketing approval in the EU. The Company also has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc.
In addition arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.
AutoImmune Disease Treatments